Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-09-05

Clinical Trial Update: Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis [Phase 2]

View source ↗

Summary

Phase 2 maximal-use study results for Tapinarof Cream 1% in pediatric patients with extensive atopic dermatitis have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tapinarof Cream (tapinarof)

Snippet

Sponsor: Organon and Co | Conditions: Atopic Dermatitis | Phase 2 | Status: COMPLETED | Results posted: 2025-09-05